Related references
Note: Only part of the references are listed.Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction
Virginia S. Hahn et al.
CIRCULATION (2023)
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF
Senthil Selvaraj et al.
CIRCULATION (2022)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich et al.
CIRCULATION (2022)
Empagliflozin in acute myocardial infarction: the EMMY trial
Dirk von Lewinski et al.
EUROPEAN HEART JOURNAL (2022)
Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF
Yan Deng et al.
CIRCULATION RESEARCH (2021)
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Javed Butler et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Sharmaine Thirunavukarasu et al.
DIABETES (2021)
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee
Thomas M. Maddox et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
B. Gaborit et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study
Jonas Oldgren et al.
DIABETES OBESITY & METABOLISM (2021)
Cardiac Energy Metabolism in Heart Failure
Gary D. Lopaschuk et al.
CIRCULATION RESEARCH (2021)
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark et al.
ESC HEART FAILURE (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Myocardial adipose deposition and the development of heart failure with preserved ejection fraction
Cho-Kai Wu et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comprehensive quantification of fuel use by the failing and nonfailing human heart
Danielle Murashige et al.
SCIENCE (2020)
Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study
Desiree Abdurrachim et al.
DIABETES OBESITY & METABOLISM (2019)
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
Roni Nielsen et al.
CIRCULATION (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Rimei Nishimura et al.
ADVANCES IN THERAPY (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction
Wei Wang et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis
Thomas A. Treibel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Innovation in Heart Failure Treatment Life Expectancy, Disability, and Health Disparities
Karen E. Van Nuys et al.
JACC-HEART FAILURE (2018)
Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice
Desiree Abdurrachim et al.
CARDIOVASCULAR RESEARCH (2018)
Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland
Mamas A. Mamas et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB
Lucian A. B. Purvis et al.
PLOS ONE (2017)
The Failing Heart Relies on Ketone Bodies as a Fuel
Gregory Aubert et al.
CIRCULATION (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy
Roger M. Beadle et al.
JACC-HEART FAILURE (2015)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolomics as a tool for cardiac research
Julian L. Griffin et al.
NATURE REVIEWS CARDIOLOGY (2011)
Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy Deficiency
Thanh T. Phan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T
D. J. Tyler et al.
NMR IN BIOMEDICINE (2009)
The creatine kinase energy transport system in the failing mouse heart
Craig A. Lygate et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
pcaMethods - a bioconductor package providing PCA methods for incomplete data
Wolfram Stacklies et al.
BIOINFORMATICS (2007)
Metabolomic identification of novel biomarkers of myocardial ischemia
MS Sabatine et al.
CIRCULATION (2005)
Is the failing heart energy starved? On using chemical energy to support cardiac function
JS Ingwall et al.
CIRCULATION RESEARCH (2004)
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
LB Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Share Paper
